West Nile virus diagnosis and vaccination: Using unique viral peptide sequences to evoke specific immune responses
Department of Biosciences, Biotechnologies and Pharmacological Sciences, University of Bari , Bari , Italy. Immunopharmacology and Immunotoxicology
(Impact Factor: 1.2).
11/2012; 35(1). DOI: 10.3109/08923973.2012.736521
West Nile virus (WNV) infection may be associated with fever, neurologic disorders, and acute flaccid paralysis as a final clinical outcome. In spite of the numerous WNV infection outbreaks in Africa, Eurasia, Australia, and North America and notwithstanding an intense research effort for developing effective anti-WNV vaccines, currently no immunopreventive or therapeutic approaches are available. Moreover, antigenic cross-reactivity among flaviviruses can make difficult WNV serodiagnosis. Here we analyze the primary sequence of WNV polyprotein searching for peptide modules that might be utilized to design targeted diagnostic tools and anti-WNV vaccines for use in humans. To this aim, we applied the low-similarity hypothesis, according to which rare peptide sequences are more likely immunogenic than frequent peptide sequences. We report on a set of peptide sequences unique to the WNV, the immunogenic potential of which appears to be confirmed by immunological data cataloged at the Immune Epitope Data Base resource.
Available from: femspd.oxfordjournals.org
- "In this regard, we already observed that a striking level of sequence identity to the human host might act as a camouflage mechanism of infectious agents (Natale et al., 2000; Tindle, 2002; Lucchese et al., 2009; Capone et al., 2013), because when high levels of sequence/structure identity are present between microbial and human molecules , the breaking of the self-tolerance mechanisms that prevent self-reactivity is highly improbable (Silverstein, 2001). Thus, the sharing of continuous aa sequences with host molecules may represent an elective microbial mechanism to escape immune recognition attack (Kanduc et al., 2008; Trost et al., 2010). "
[Show abstract] [Hide abstract]
ABSTRACT: Epstein-Barr virus proteins were examined for amino acid sequence matching to human proteins at the decapeptide level. We report that numerous EBV peptides of different length (from 10- to 13-mer) are present in 28 human proteins. The viral versus human peptide overlap mainly involves the glycine-rich region allocated in the NH2-terminus of Epstein-Barr nuclear antigen 1 protein and host cellular components that play crucial roles in basic biochemical pathways, such as chromatin remodelling, RNA splicing, transmission across chemical/electrical synapses, neurogenesis, and that, when altered, may characterize various pathologies such as immunodeficiency, systemic lupus erythematosus, myelination, and speech disorders. The present results might contribute to understand and define the (physio)pathological relationships and interactions occurring between EBV and the human host. This article is protected by copyright. All rights reserved.
FEMS Immunology & Medical Microbiology 07/2013; 69(3). DOI:10.1111/2049-632X.12066 · 3.08 Impact Factor
[Show abstract] [Hide abstract]
ABSTRACT: Defining the minimal protein determinants of enzymic reactions, biological interactions, and immune recognition is at the core of biochemistry, pathology and therapeutics. Indeed, short peptide sequences are involved in physiological processes such as cell growth and apoptosis, and in pathological phenomena such as amyloid protein fibrillogenesis and tumor cell migration. An active peptide may exert more powerful activity than the entire parent protein and, in immunology, use of short peptides may improve immunotherapies and avoid the potential hazards of using full-length protein antigens. This review illustrates the concept that a peptide sequence only 5-residues long may be used as a basic functional unit in cell biology and immunology, underlines the crucial biological roles played by minisequences and emphasizes the multifold applications of short peptides as therapeutic agents.
Current Protein and Peptide Science 12/2012; 14(2). DOI:10.2174/1389203711314020003 · 3.15 Impact Factor
[Show abstract] [Hide abstract]
ABSTRACT: Epidemiologic data suggest that maternal microbial infections may cause fetal neurodevelopmental disorders, potentially increasing susceptibility to heavy psychopathologies such as schizophrenia, schizophreniform disorder, autism, pervasive developmental disorders, bipolar disorders, psychosis, epilepsy, language and speech disorders, and cognitive impairment in adult offspring. However, the molecular pathomechanisms underlying such a relationship are not clear. Here we analyze the potential role of the maternal immune response to viral infection in determining fetal brain injuries that increase the risk of neurological disorders in the adult. We use influenza infection as a disease model and human axon guidance pathway, a key process in the formation of neural network during midgestation, as a potential fetal target of immune insults. Specifically, we examined influenza A H1N1 hemagglutinin (HA), an antigenic viral protein, for amino acid sequence similarity to a random library of 188 axon guidance proteins. We obtain the results that (1) contrary to any theoretical expectations, 45 viral pentapeptide matches are distributed throughout a subset of 36 guidance molecules; (2) in 24 guidance proteins, the peptide sharing with HA antigen involves already experimentally validated influenza HA epitopes; and (3) most of the axon guidance vs HA peptide overlap is conserved among influenza A viral strains and subsets. Taken together, our data indicate that immune cross-reactivity between influenza HA and axon guidance molecules is possible and may well represent a pathologic mechanism capable of determining neurodevelopmental disruption in the fetus.
Schizophrenia Bulletin 01/2013; 40(2). DOI:10.1093/schbul/sbs197 · 8.45 Impact Factor
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.